Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis.

Mycophenolate mofetil (MMF) inhibits purine synthesis by inhibiting inosine-5'-monophosphate dehydrogenase. Since 1995, it has been approved in the USA for the prevention of allograft rejection in solid organ transplant patients. In the last two decades, it has been frequently used as an immunosuppressive therapy for numerous autoimmune conditions including lupus nephritis.

Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis.

Introduction: Disease expression and outcomes in rheumatoid arthritis (RA) vary among different ethnic groups. There are limited data on the impact of age on disease severity and outcomes among Hispanics. Thus, we determined the demographic characteristics, clinical manifestations, comorbidities, pharmacologic profile, and functional status among Puerto Ricans with RA of different age groups.